PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34382102-5	2021	RESULTS: Individual pretreatments of rats with montelukast, diclofenac, or celecoxib partly reduced formalin-induced increases in (i) paw edema, fibrosis, and inflammatory cells, (iii) serum interleukin-6 (IL-6) and leukotrienes (LTB4 and LTD4), and (iv) paw expressions of inducible nitric oxide synthase (iNOS) and COX2.	montelukast	47-58	nitric oxide synthase 2	Rattus norvegicus	274-305	
34382102-5	2021	RESULTS: Individual pretreatments of rats with montelukast, diclofenac, or celecoxib partly reduced formalin-induced increases in (i) paw edema, fibrosis, and inflammatory cells, (iii) serum interleukin-6 (IL-6) and leukotrienes (LTB4 and LTD4), and (iv) paw expressions of inducible nitric oxide synthase (iNOS) and COX2.	montelukast	47-58	nitric oxide synthase 2	Rattus norvegicus	307-311	
34382102-9	2021	CONCLUSIONS: While montelukast equally enhances antiinflammatory action of diclofenac or celecoxib via downregulating iNOS/COX2/LTs/IL-6 signaling, its gastroprotective action is preferentially potentiated by celecoxib.	montelukast	19-30	nitric oxide synthase 2	Rattus norvegicus	118-122	
30056375-16	2018	Moreover, immunohistochemical examination revealed that montelukast markedly reduced iNOS expression, while expression of PTEN was markedly enhanced, as compared to EV group.	montelukast	56-67	nitric oxide synthase 2	Rattus norvegicus	85-89	
30056375-18	2018	CONCLUSIONS: Montelukast in dose dependant manner provided biochemical and histo-pathological improvement in EV induced EH, through its anti-inflammatory, antioxidant activity and inhibition of iNOS expression with induction of PTEN expression.	montelukast	13-24	nitric oxide synthase 2	Rattus norvegicus	194-198	
14991993-7	2003	Montelukast sodium activated the eNOS expression and reduced the iNOS expression.	montelukast	0-18	nitric oxide synthase 2	Rattus norvegicus	65-69	
14991993-8	2003	CONCLUSION: Montelukast sodium is cardioprotective during myocardial injury in rats by halting the leukotrienes-induced inflammatory response and upregulating the eNOS expression as well as downregulating the iNOS expression.	montelukast	12-30	nitric oxide synthase 2	Rattus norvegicus	209-213	
14559427-2	2003	This study investigated the effects of montelukast (a leukotriene receptor antagonist) on iNOS expression and activity in a Brown Norway (BN) rat allergic inflammation model and in L2 lung epithelial cells.	montelukast	39-50	nitric oxide synthase 2	Rattus norvegicus	90-94	
14559427-7	2003	iNOS expression was significantly higher in OVA challenged rats compared to the naive, DX, and montelukast treated groups, as confirmed by immunohistochemistry and Western blot analysis.	montelukast	95-106	nitric oxide synthase 2	Rattus norvegicus	0-4	
14559427-11	2003	Treatment of cytokine stimulated cells with DX or montelukast significantly decreased iNOS expression and activity.	montelukast	50-61	nitric oxide synthase 2	Rattus norvegicus	86-90	
14559427-13	2003	This study confirms the ability of montelukast to modulate iNOS function and raises the possibility that changes in iNOS expression and activity may occur via pathways independent of cysteinyl leukotrienes.	montelukast	35-46	nitric oxide synthase 2	Rattus norvegicus	59-63	
26328182-0	2014	Montelukast prevents testes against ischemia-reperfusion injury through suppression of iNOS expression.	montelukast	0-11	nitric oxide synthase 2	Rattus norvegicus	87-91	
26328182-15	2014	CONCLUSION: Montelukast exerts protective effects against testicular I/R injury by inhibiting neutrophil activity, reversing the oxidative stress markers, decreasing iNOS activity and attenuating apoptosis.	montelukast	12-23	nitric oxide synthase 2	Rattus norvegicus	166-170